Q2 2024 EPS Estimates for Omnicell, Inc. Reduced by Analyst (NASDAQ:OMCL)

Omnicell, Inc. (NASDAQ:OMCL) – Stock analysts at Zacks Research lowered their Q2 2024 earnings per share (EPS) estimates for Omnicell in a research note issued to investors on Tuesday, April 16th. Zacks Research analyst M. Mondal now anticipates that the company will post earnings of $0.00 per share for the quarter, down from their prior estimate of $0.07. The consensus estimate for Omnicell’s current full-year earnings is $0.09 per share. Zacks Research also issued estimates for Omnicell’s FY2024 earnings at $0.08 EPS, Q2 2025 earnings at $0.10 EPS, Q3 2025 earnings at $0.08 EPS, Q4 2025 earnings at $0.12 EPS, FY2025 earnings at $0.29 EPS and Q1 2026 earnings at $0.09 EPS.

OMCL has been the subject of several other research reports. Benchmark lowered their price target on Omnicell from $42.00 to $38.00 and set a “buy” rating for the company in a report on Friday, February 9th. Barclays assumed coverage on Omnicell in a research report on Wednesday, January 3rd. They set an “underweight” rating and a $33.00 price target for the company. Finally, Wells Fargo & Company cut their price objective on Omnicell from $28.00 to $26.00 and set an “equal weight” rating for the company in a research report on Friday, February 9th. One research analyst has rated the stock with a sell rating, three have given a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $42.20.

Omnicell Stock Performance

Shares of Omnicell stock opened at $27.83 on Thursday. The firm has a market cap of $1.28 billion, a P/E ratio of -61.84 and a beta of 0.76. The company has a current ratio of 2.52, a quick ratio of 2.22 and a debt-to-equity ratio of 0.48. Omnicell has a 12 month low of $25.69 and a 12 month high of $77.14. The stock’s fifty day moving average price is $27.73 and its 200-day moving average price is $32.89.

Omnicell (NASDAQ:OMCL) last released its earnings results on Thursday, February 8th. The company reported $0.12 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.22. Omnicell had a positive return on equity of 3.43% and a negative net margin of 1.78%. The business had revenue of $258.85 million for the quarter, compared to analyst estimates of $256.00 million.

Hedge Funds Weigh In On Omnicell

Several large investors have recently modified their holdings of the business. Avory & Company LLC lifted its stake in Omnicell by 22.7% during the 3rd quarter. Avory & Company LLC now owns 153,776 shares of the company’s stock worth $6,926,000 after acquiring an additional 28,416 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of Omnicell by 15.1% in the 3rd quarter. Vanguard Group Inc. now owns 5,137,084 shares of the company’s stock valued at $231,374,000 after purchasing an additional 674,824 shares during the period. Pacer Advisors Inc. boosted its position in shares of Omnicell by 321,488.8% in the 4th quarter. Pacer Advisors Inc. now owns 1,058,027 shares of the company’s stock valued at $39,814,000 after purchasing an additional 1,057,698 shares during the period. Public Sector Pension Investment Board acquired a new stake in Omnicell during the 3rd quarter worth approximately $2,517,000. Finally, Ontario Teachers Pension Plan Board acquired a new stake in Omnicell during the 3rd quarter worth approximately $984,000. Institutional investors and hedge funds own 97.70% of the company’s stock.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.